<DOC>
	<DOCNO>NCT02148718</DOCNO>
	<brief_summary>Rapidity response treatment inflammatory bowel disease consider field major interest , due importance achieve high benefit shortest possible time , order favor fast backward step normal life . There previous study specifically design evaluate rapidity response adalimumab therapy patient active Crohn 's disease . Studies rapidity onset response adalimumab , hand , perform disease rheumatoid arthritis ( Efficacy HUMIRA Subjects With Active Rheumatoid Arthritis HERO study , Wolfe et al , 2006 ) . This trial assess clinical response occur early week 1 . This open label , one arm , prospective , multicenter , phase IV clinical trial .</brief_summary>
	<brief_title>Rapidity Response Adalimumab Treatment Patients With Crohn´s Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Crohn 's disease diagnose within , least , previous 4 month . Patients active luminal ( HarveyBradshaw Index ≥8 ) moderate severe Crohn´s disease . No response full adequate course therapy corticosteroid and/or immunosuppressant . If receive follow treatment , dose stable period indicate : Aminosalicylates , least , last 4 week Probiotics , least , last 4 week Analgesics , least , last 4 week Antidiarrheals , least , last 4 week CDrelated antibiotic , least , last 4 week Azathioprine , 6mercaptopurine methotrexate , least , last 12 week If receive follow treatment , dose increase past two week ( dose reduction permit ) : Oral budesonide ( maximum dose 9 mg/day ) Oral prednisone equivalent ( maximum dose 40mg/day ) Previous treatment antiTumor Necrosis Factor agent . Surgical bowel resection within previous 6 month , ostomy , extensive bowel resection ( &gt; 100 cm ) , short bowel syndrome , Fistulising Crohn 's disease . Treatment cyclosporine tacrolimus within previous 8 week . Clinically significant cardiac disease include unstable angina , acute myocardial infarction within six month screen , congestive heart failure bad grade II New York criterion ( New York Heart Association Functional Classification ) . Subject ostomy ileoanal pouch , proctocolectomy , total colectomy , ileostomy , stoma ileal pouchanal anastomosis ( Subjects previous ileorectal anastomosis exclude ) . Screening laboratory value ( accord central laboratory ) Known hepatitis C ( HC ) infection . Serologic evidence hepatitis B ( HB ) infection base result test hepatitis B surface antigen ( HBsAg ) , hepatitis B core antibody ( antiHBc ) hepatitis B surface antibody ( antiHBs ) antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Crohn 's Disease</keyword>
</DOC>